A Review of Emerging ARNI Data in HFrEF

  • Published:  27 November 2019
  • Likes: 

    Heart Icon

    1

Up Next

A Review of Emerging ARNI Data in HFrEF

  • Published:  27 November 2019
  • Likes: 

    Heart Icon

    1

Average (ratings)
No ratings
Your rating
Overview

Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.

Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.

Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.

This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
 

EBAC Accreditation

This video series was funded by an unrestricted educational grant from Novartis.

Educational Objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019
  • Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
  • Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
  • Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.

More from this programme

Part 1

ARIADNE in Review

Part 2

Commentary on ARIADNE

Part 3

PROVE-HF in Review

Part 4

EVALUATE in Review

Part 5

Commentary on PROVE-HF and EVALUATE

Part 6

TRANSITION-CHF in Review

Part 7

PIONEER in Review

Part 8

Commentary on TRANSITION-CHF and PIONEER

Faculty Biographies

Scott Solomon

Scott Solomon

Director, Noninvasive Cardiology / Professor

Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction. 

He received his AB from Williams College and his MD from Harvard Medical School. 

View full profile
Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.

 

Career Overview

Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.

View full profile